Cellectar biosciences announces one-for-thirty reverse stock split

Florham park, n.j., june 18, 2025 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a one-for-thirty reverse stock split (the “reverse stock split”) of the company's common stock, par value $0.00001, which will become effective at 12:01 a.m. eastern time on tuesday, june 24, 2025. the company's common stock will continue to trade under its current trading symbol, clrb, on the nasdaq global select market (“nasdaq”) on a split-adjusted basis when the market opens on tuesday, june 24, 2025, with the new cusip number 15117f880.
CLRB Ratings Summary
CLRB Quant Ranking